INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 196 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q1 2020. The put-call ratio across all filers is 0.92 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $735 | +293.0% | 54,751 | +261.1% | 0.07% | +257.9% |
| Q4 2022 | $187 | -99.9% | 15,163 | +208.3% | 0.02% | -68.3% |
| Q1 2020 | $310,000 | +30.8% | 4,918 | +108.5% | 0.06% | +46.3% |
| Q4 2018 | $237,000 | -71.2% | 2,359 | -65.3% | 0.04% | -73.7% |
| Q2 2017 | $824,000 | +99.0% | 6,798 | +85.6% | 0.16% | +60.8% |
| Q1 2017 | $414,000 | – | 3,662 | – | 0.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 640,688 | $9,514,000 | 1.49% |
| CM Management, LLC | 45,000 | $668,000 | 0.50% |
| EULAV Asset Management | 660,000 | $9,801,000 | 0.26% |
| DLD Asset Management, LP | 225,200 | $3,346,000 | 0.24% |
| Virtus ETF Advisers LLC | 21,387 | $318,000 | 0.14% |
| GSA CAPITAL PARTNERS LLP | 79,145 | $1,175,000 | 0.12% |
| Hennion & Walsh Asset Management, Inc. | 136,720 | $2,030,000 | 0.11% |
| ALTRINSIC GLOBAL ADVISORS LLC | 168,800 | $2,507,000 | 0.08% |
| Inspire Investing, LLC | 31,868 | $473,000 | 0.06% |
| DUALITY ADVISERS, LP | 51,196 | $760,000 | 0.06% |